Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists

Joint Bone Spine

Volumn 73, Issue 6, 2006, Pages 718-724

  Kamal, Khalid M ^a   Madhavan, S Suresh ^b   Hornsby, Jo Ann Allen ^c   Miller, Lesley Ann ^b   Kavookjian, Jan ^b   Scott, Virginia ^b  

^a BAYER CORPORATION   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; Survey

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; TREATMENT RESPONSE; UNITED STATES; DRUG ANTAGONISM; INFORMATION PROCESSING; MIDDLE AGED; POSTAL MAIL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATA COLLECTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POSTAL SERVICE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 33845593147     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.05.002     Document Type: Article

References (37)

1. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27 (2001) 269-281
2. American College of Rheumatology (ACR) Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 46 (2002) 328-346
3. Griffiths R.I., Bar-Din M., MacLean C., Sullivan E.M., Herbert R.J., and Yelin E.H. Patterns of disease modifying antirheumatic drug use, medical resources consumption, and cost among rheumatoid arthritis patients. Ther. Apher. 5 (2001) 92-104
4. Pugner K.M., Scott D.I., Holmes J.W., and Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29 (2000) 305-320
5. Yazici Y., Erkan D., and Paget S.A. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum. 48 (2003) 2769-2772
6. Kremer J.M. Rational use of new and existing disease modifying agents in rheumatoid arthritis. Ann. Intern. Med. 134 (2001) 695-706
7. Hochberg M.C., Tracy J.K., Hawkins-Holt M., and Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl II (2003) ii13-iii6
8. Louie S.G., Park B., and Yoon H. Biological response modifiers in the management of rheumatoid arthritis. Am. J. Health Syst. Pharm. 60 (2003) 346-355
9. Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 289 (2003) 3229-3230
10. Kavanaugh A., Cohen S., and Cush J.J. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J. Rheumatol. 31 (2004) 1881-1884
11. Michaud K., Messer J., Choi H.K., and Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a 3-year study of 7,527 patients. Arthritis Rheum. 48 (2003) 2750-2762
12. Fleischmann R., and Yocum D. Does safety make a difference in selecting the right TNF antagonist?. Arthritis Res. Ther. 6 Suppl 2 (2004) S12-SS8
13. Schwartzman S., and Morgan G.J. Does route of administration affect the outcome of TNF antagonist therapy?. Arthritis Res Ther 6 Suppl 2 (2004) S19-S23
14. Schwartzman S., Fleischmann R., and Morgan G.J. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?. Arthritis Res. Ther. 6 Suppl 2 (2004) S1-S3
15. Jobanputra P., Wilson J., Douglas K., and Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatol. 43 (2004) 206-210
16. Maetzel A., Bombardier C., Strand V., Tugwell P., and Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J. Rheumatol. 25 (1998) 2331-2338
17. Pope J.E., Hong P., and Koehler B.E. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of Canadian rheumatologists. J. Rheumatol. 29 (2002) 255-260
18. Wolfe F., Albert D.A., and Pincus T. A survey of United States rheumatologists concerning effectiveness of disease modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. Arthritis Care Res. 11 (1998) 375-380
19. Introduction to survey sampling. In: Kalton G. (Ed). Sage University paper series on quantitative application in social sciences (1987), Sage Publications, Beverly Hills and London
20. Wolfe F., Rehman Q., Lane N.E., and Kremer J. Starting a disease modifying antirheumatic drug or biologic agent in Rheumatoid arthritis: standards of practice for RA treatment. J. Rheumatol. 28 (2001) 1704-1711
21. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
22. Smolen J., van der Heijde D., and Emery P. Infliximab inhibits radiographic joint damage in patients with early rheumatoid arthritis regardless of clinical response after 54-week treatment. Ann. Rheum. Dis. 63 Suppl. I (2004) 260
23. Erkan D., Yazici Y., Harrison M.J., and Paget S.A. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum. 47 (2002) 285-290
24. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363 (2004) 675-681
25. Choy E.H. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatol. 43 (2004) 1205-1207
26. Schnabel A. Disease modifying antirheumatic drugs: enhancing efficacy by combination. Lancet 363 (2004) 670-671
27. Maravic M., Berge C., Daures J.P., and Boissier M.C. Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. Clin. Exp. Rheumatol. 23 (2005) 36-42
28. van Vollenhoven R.F. Switching between biologicals. Clin. Exp. Rheumatol. 22 Suppl.35 (2004) S115-SS21
29. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?. J. Rheumatol. 31 (2004) 1021-1022
30. Ledingham J., Wilkinson C., and Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatol. 44 (2005) 1205-1206
31. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60 (2005) 800-805
32. Maravic M., Daures J.P., and Boissier M.C. Clinical practices among rheumatologists: managing patients with rheumatoid arthritis. Joint Spine Bone 69 (2002) 270-274
33. Emery P., Reginster J.Y., Appelboom T., Breedveld F.C., Edelmann E., Kekow J., et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatol. 40 (2001) 699-702
34. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann. Rheum. Dis. 64 Suppl 4 (2005) iv2-iv14
35. Gallup E. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting. Manag Care Interface 14 (2001) 52-54 (57-8, 69)
36. Chao C.S. Physicians attitudes towards DNR of terminally ill cancer patients in Taiwan. J. Nurs. Res. 10 (2002) 161-167
37. Zeirler B.K., Meissner M.H., Cain K., and Strandness D.E. A survey of physicians' knowledge and management of venous thromboembolism. Vas Endovascular Surg 36 (2002) 367-375